Jason Murphy Email & Phone Number

As CEO and Co-Founder of Electron Bio, I lead a pioneering biomanufacturing company focused on overcoming the key challenges in biotech manufacturing—reducing costs, improving quality, and ensuring timely delivery of life-saving therapies. At Electron Bio, we are dedicated to streamlining biomanufacturing processes to accelerate the availability of.

Cambridge, Massachusetts, US

• Spearheaded the integration and strategic realignment of Moderna's DNA, enzymes, and chemical products division, ensuring critical contributions to COVID vaccine production amidst unprecedented global demand..
• Established Moderna's inaugural business unit for complex biological feedstocks, pivotal in mRNA therapies.
• Directed the comprehensive management of DNA and lipid production, co-transcriptional caps, and enzymes crucial for RNA/DNA manufacturing, supporting Moderna’s portfolio including COVID vaccine initiatives.
• Led a cross-functional leadership team across operations, R&D, manufacturing science and technology (MST), supply chain, digital innovation, and more, enhancing productivity and strategic foresight.
• Appointed as the Norwood Site Biosafety Officer, liaising with local authorities and safeguarding biological safety protocols for a significant portion of Moderna's internal manufacturing and technical development.

Cambridge, Massachusetts, US

• Pioneered groundbreaking advancements in mRNA, DNA, and enzyme process development at Moderna, steering 100+ scientists and engineers to achieve pivotal milestones in COVID vaccine development and the commercialization.
• Managed a specialized team in high-throughput development and automation engineering, enhancing productivity and innovation in equipment design and process optimization.
• Directed the Personalized Vaccine Process Development initiative, introducing advanced methodologies for Phase II and III manufacturing, paving the way for the commercialization of groundbreaking personalized cancer.
• Accelerated the manufacturing platform for COVID vaccine Phase I clinical trials, demonstrating the capability to rapidly adapt and respond to global health emergencies.
• Led the strategic acquisition of OriCiro, a DNA synthesis company, for approximately $85M, showcasing my critical role in due diligence, negotiation, and strategic planning alongside Moderna’s executive team.
• Actively participated in key committees including the Moderna Genomics Joint Steering Committee as CMC Lead, influencing the direction of gene editing and other advanced genomic projects. Also contributed to the.

Indianapolis, Indiana, US

• Elevated Elanco’s biopharmaceutical and vaccine divisions through strategic leadership in fermentation development and strain innovation, guiding a 25+ person team and the overall Fermentation Development Technical.
• Orchestrated successful technology transfers for key biotechnology products, facilitating the modernization and commercial launch of enzymes, antibodies, and similar products. This initiative directly supported.
• Spearheaded comprehensive productivity initiatives across biotechnology sectors (including natural and nutritional products, biopharmaceuticals, and vaccines), driving enhancements in product filings and technical.
• Provided expert consultancy to Elanco’s vaccine business, impacting R&D activities for products generating over $200M and contributing to a total annual revenue of $500M. My strategic insights and leadership bolstered.

Indianapolis, Indiana, US

• At the helm of Elanco's biotech and fermented products network, I led pivotal operations across multiple sites (Augusta, GA; Clinton, IN; Liverpool, UK), driving initiatives that supported about 50% of Elanco’s.
• Spearheading the biotech and fermented products network, ensuring robust support for Elanco’s major revenue-generating products across natural, biopharmaceutical, and nutritional categories. My leadership in this area.
• Conducting thorough evaluations of productivity, risk tracking, and remediation efforts, alongside direct engagement with high-profile issues, highlighting my commitment to operational excellence and continuous.
• Leading a resolute 25+person team in animal health fermentation development, focusing on cutting-edge strain development and fermentation processes, thus reinforcing Elanco’s capabilities in fermentation and strain.
• Establishing the biotech and fermented products network science lead team, demonstrating my initiative in fostering a collaborative environment that promotes scientific innovation and operational efficiency within.

• Pioneered downstream process development and commercialization strategies for late-stage vaccines, leading a dynamic team of ~20+ professionals. As a vital contributor to Phase III and licensed vaccine projects, my.
• Spearheading technology transfers and form/fill operations to the Durham, NC site, where I also took on the role of new technology leader for vaccine commercialization. This key initiative supported both new and.
• Innovating in live virus vaccine cell culture, downstream purification, and characterization with a dedicated team of ~25 professionals, enhancing the scalability and quality of vaccine production.
• Co-leading the technical product council for a vaccine franchise worth over $2B, demonstrating my strategic acumen in steering high-value vaccine projects to commercial success.
• My tenure at GVBC was marked by strategic leadership in vaccine process development and commercialization, underpinning significant advancements in vaccine accessibility and public health impact.

Led Viral Vaccine Process Development and Downstream Polysaccharide Process Development.

Interim Department Head of Viral Vaccine Process Development

• Spearheaded downstream process development for Merck’s premier vaccine family, leading both enhancements of existing processes and the development of next-generation methodologies with a specialized team of ~10+.
• Directed the downstream technology transfer, enhancing Merck's vaccine production capabilities and ensuring seamless integration of advanced manufacturing processes.
• Initiated and led the development of improved formulation and filling methods with a ~15+ person team, focusing on late-phase vaccine projects to increase manufacturing process robustness and capabilities, crucial for.
• Successfully led a project from 2012 to 2014 aimed at increasing the reliability of key marketed vaccines through advanced formulation development, marking a significant contribution to vaccine stability and.

• At the forefront of Merck Research Laboratories' Pharmaceutical Sciences division, I led the charge in RNA therapeutics formulation, pioneering process development and scale-up with a keen focus on revolutionary.
• Spearheading the formulation process development for RNA therapeutics, emphasizing innovative delivery platforms that are now foundational to the field. This included navigating the complexities of lipid nanoparticle.
• Overseeing a multidisciplinary team responsible for process optimization, analytical validation, and formulation development, ensuring the seamless progression of projects from concept through to scale-up.
• Playing a key role in Merck's strategic investment in RNA technology, providing both the vision and scientific expertise necessary to leverage Sirna Therapeutics' capabilities, thereby bolstering Merck's position in.

• At Merck, I led groundbreaking biopharmaceutical research and development with a focus on biopurification for high-profile vaccine programs, contributing to projects with annual sales reaching into the billions..
• Spearheaded downstream processing and troubleshooting for a live virus vaccine franchise, securing its status as a billion-dollar enterprise.
• Directed comprehensive process development and clinical manufacture for DNA/viral vaccines, significantly advancing Merck’s portfolio in cancer vaccine research.
• Managed multiple GMP campaigns to produce clinical supplies for various high-stakes programs, underscoring my expertise in ensuring product quality and compliance.
• Led adenovirus purification process development for an HIV vaccine, demonstrating my commitment to tackling global health challenges through innovative bioprocessing techniques.
• Conducted pivotal research on DNA vaccine process development, enhancing Merck's capabilities in vaccine innovation and delivery.My tenure at Merck was marked by leadership in bioprocess research and development.

Phd, Chemical Engineering

B.S., Chemical Engineering